ORIC Pharmaceuticals SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 07, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing ...

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Feb. 18, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that ...

In other ORIC Pharmaceuticals news, CEO Jacob Chacko sold 24,660 shares of the company’s stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of ...

Reported encouraging early safety and efficacy data in ongoing dose escalation trial for ORIC-944 in combination with androgen receptor inhibitors in patients with mCRPC Entered into clinical ...

Shares of ORIC opened at $8.03 on Wednesday. ORIC Pharmaceuticals has a 52-week low of $6.33 and a 52-week high of $16.65. The firm’s fifty day moving average is $9.27 and its two-hundred day ...

At least 24 termination letters have been sent out, according to one official. Several active research grants related to studies involving LGBTQ+ issues, gender identity and diversity, equity and ...

(RTTNews) - ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical-stage oncology company, announced its refined registrational clinical development plans for its lead programs, ORIC-944 and ORIC ...

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 07, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address ...

Reported encouraging early safety and efficacy data in ongoing dose escalation trial for ORIC-944 in combination with androgen receptor inhibitors in patients with mCRPC Entered into clinical ...

It came from the Department of Health and Human Services, which oversees the NIH, and arrived with clear instructions: Post this announcement on your website immediately. The memo announced a new ...

ORIC Pharmaceuticals outlines clinical development plans for ORIC-944 and ORIC-114, targeting high unmet needs in mCRPC and NSCLC. ORIC Pharmaceuticals has refined its registrational development ...